Arena Pharmaceuticals Inc. (ARNA): Today's Featured Drugs Winner
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
.
(
) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.1%. By the end of trading, Arena Pharmaceuticals rose 68 cents (7.9%) to $9.32 on average volume. Throughout the day, 22.1 million shares of Arena Pharmaceuticals exchanged hands as compared to its average daily volume of 23.5 million shares. The stock ranged in a price between $8.71-$9.35 after having opened the day at $8.77 as compared to the previous trading day's close of $8.64. Other companies within the Drugs industry that increased today were:
(
), up 13.8%,
(
), up 12.9%,
(
TheStreet Recommends
), up 11.3%, and
(
), up 9.5%.
- ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!
Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena Pharmaceuticals has a market cap of $1.45 billion and is part of the
sector. Shares are up 362% year to date as of the close of trading on Friday. Currently there are two analysts that rate Arena Pharmaceuticals a buy, one analyst rates it a sell, and six rate it a hold.
TheStreet Ratings rates Arena Pharmaceuticals as a
. Among the areas we feel are negative, one of the most important has been poor profit margins.
- You can view the full Arena Ratings Report.
On the negative front,
(
), down 15%,
(
), down 10%,
(
), down 9.5%, and
(
), down 8.7%, were all laggards within the drugs industry with
(
) being today's drugs industry laggard.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null
